ABSTRACT
This study was designed to evaluate the antihyperlipidemic effects of high dose aspirin in obese hyperlipedemic rabbits. Forty obese Rabbits were used in this study. These rabbits were made hyperlipedemic by injecting 150mg/kg of Intravenous alloxan. Blood samples were collected to find the lipid profile before starting the various therapies. Rabbits were divided randomly into 4 groups [10 each], Misoprostol [200 micro g] orally was given before and during the therapy whereas the therapies assigned to different groups for 15 days were as follows: Group A was hyperlipedemic control and received placebo orally. Group B received Glibenclamide [10mg/kg] orally. Group C was given Aspirin low dose [50mg/kg] orally. Group D received Aspirin high dose [120mg/kg] orally. Serum cholesterol, LDL-cholesterol, triglyceride and HDL levels were estimated by enzymatic and point kits method manufactured by Randox UK. One-way analysis of variance [ANOVA] was applied by using SPSS 16 version and P value was
ABSTRACT
This study was designed to evaluate the anti diabetic effects of high dose aspirin in rabbits. In this study 40 obese rabbits were used and zero day fasting blood glucose levels were determined to establish the values before treatment for all the animals. Intravenous alloxan 150mg/ kg was given to induce diabetes in these rabbits. Rabbits having glucose level more than 200 mg/dl were considered to be diabetic. Before starting the various therapies blood samples were collected to find the glucose levels. Misoprostol [200 [ig] was given orally before and during the therapy to minimize the gastric side effects of Aspirin high doses. Study was designed for 15 days and rabbits were randomly divided into 4 groups according to the therapies assigned: Group A was diabetic control and received placebo orally. Group B received Glibenclamide [l0mg/kg] orally. Group C was given Aspirin in low dose [50mg/kg] orally. Group D received Aspirin in high dose [120mg/kg] orally. Serum glucose was estimated by enzymatic end point kit method manufactured by Randox UK. One-way analysis of variance [ANOVA] was applied by using SPSS 16 version and P value < 0.05 was considered as significant. Zero day fasting serum blood glucose values were determined after diabetes had been induced. At the end of study the reduction in fasting blood glucose level was maximum with glibenclamide 56.31% as compared to low dose aspirin 14.49% and high dose aspirin 23.91%. High dose aspirin resulted in significant reduction in fasting blood glucose level due to enhanced insulin sensitivity. High dose salicylates [120mg/kg aspirin] inhibit IKK [3 activity, and reverse hyperglycaemia and hyperinsulinemia by sensitizing insulin signalling. Although high dose aspirin could not be used for treatment of type 2 diabetes, on the basis of findings of this study it is suggested that IKK [3 pathway may represent a new approach for treating this disease. This study provides a novel approach in drug design to treat hyperglycemias in obese diabetic rabbits